一项评估不良事件以及静脉 (IV) 输注 Telisotuzumab Vedotin (ABBV-399) 作为单一疗法如何在既往接受过治疗的非鳞状非小细胞肺癌 (NSCLC) 成年参与者体内移动的研究
对既往接受过 c-Met 过表达、EGFR 野生型、局部晚期/转移性非鳞状非小细胞肺癌受试者的两种 Telisotuzumab Vedotin 治疗方案进行的 2 期、开放标签、随机、全球研究
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:ABBVIE CALL CENTER
- 电话号码:844-663-3742
- 邮箱:abbvieclinicaltrials@abbvie.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、101149
- 招聘中
- Beijing Chest Tumor Hospital /ID# 271935
-
-
Fujian
-
Fuzhou、Fujian、中国、350014
- 招聘中
- Fujian Province Cancer Hospital /ID# 276178
-
-
Guangxi
-
Nanning、Guangxi、中国、530021
- 招聘中
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150081
- 招聘中
- Harbin Medical University Cancer Hospital /ID# 271665
-
-
Henan
-
Zhengzhou、Henan、中国、450008
- 招聘中
- Henan Cancer Hospital /ID# 271927
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- 招聘中
- Union Hospital - Tongji Medical College /ID# 271668
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- 招聘中
- The First Affiliated Hospital of Nanchang University /ID# 271666
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710061
- 招聘中
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
-
-
Shandong
-
Linyi、Shandong、中国、276001
- 招聘中
- LinYi Cancer Hospital /ID# 272068
-
-
Xinjiang
-
Ürümqi、Xinjiang、中国、830011
- 招聘中
- Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
-
-
-
-
-
Haifa、以色列、3109601
- 招聘中
- Rambam Health Care Campus- Haifa /ID# 270078
-
Jerusalem、以色列、9103102
- 完全的
- Shaare Zedek Medical Center /ID# 270095
-
-
Central District
-
Kefar Sava、Central District、以色列、4428164
- 招聘中
- Meir Medical Center /ID# 270071
-
Petah Tikva、Central District、以色列、4941492
- 招聘中
- Rabin Medical Center. /ID# 270087
-
-
Tel Aviv
-
Ramat Gan、Tel Aviv、以色列、5265601
- 招聘中
- The Chaim Sheba Medical Center /ID# 270068
-
-
-
-
Beograd
-
Belgrade、Beograd、塞尔维亚、11000
- 招聘中
- Institute for Oncology and Radiology of Serbia /ID# 270561
-
Belgrade、Beograd、塞尔维亚、11080
- 招聘中
- Clinical Hospital Center - Bezanijska Kosa /ID# 270558
-
Belgrade、Beograd、塞尔维亚、11000
- 招聘中
- University Clinical Center Serbia /ID# 270808
-
Belgrade、Beograd、塞尔维亚、11000
- 招聘中
- Military Medical Academy /ID# 279873
-
-
Nisavski Okrug
-
Niš、Nisavski Okrug、塞尔维亚、18300
- 招聘中
- University Clinical Center Nis /ID# 270557
-
-
Sremski Okrug
-
Kamenitz、Sremski Okrug、塞尔维亚、21208
- 招聘中
- Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
-
-
Sumadijski Okrug
-
Kragujevac、Sumadijski Okrug、塞尔维亚、34000
- 招聘中
- University Clinical Center Kragujevac /ID# 275773
-
-
-
-
-
São Paulo、巴西、01323-020
- 招聘中
- Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
-
-
Ceará
-
Fortaleza、Ceará、巴西、60810-180
- 招聘中
- Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
-
-
Paraná
-
Curitiba、Paraná、巴西、80510-130
- 招聘中
- Ictrials Pesquisa E Desenvolvimento /ID# 276681
-
-
Pará
-
Belém、Pará、巴西、66063-495
- 招聘中
- Cto - Centro De Tratamento Oncologico /ID# 276699
-
-
Pernambuco
-
Recife、Pernambuco、巴西、50040-000
- 招聘中
- Hospital De Cancer De Pernambuco /ID# 276104
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、巴西、59075-740
- 招聘中
- Liga Norte Riograndense Contra O Cancer /ID# 273183
-
-
Rio Grande do Sul
-
Ijuí、Rio Grande do Sul、巴西、98700-000
- 招聘中
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
-
-
Santa Catarina
-
Florianópolis、Santa Catarina、巴西、88020-210
- 招聘中
- Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
-
-
-
-
Central Singapore
-
Singapore、Central Singapore、新加坡、169611
- 招聘中
- National Cancer Centre Singapore /ID# 271499
-
Singapore、Central Singapore、新加坡、119074
- 招聘中
- National University Hospital /ID# 271700
-
-
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、466-8560
- 招聘中
- Nagoya University Hospital /ID# 277010
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-8577
- 招聘中
- National Cancer Center Hospital East /ID# 277056
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、060-8648
- 招聘中
- Hokkaido University Hospital /ID# 277014
-
-
Hyōgo
-
Kobe、Hyōgo、日本、650-0046
- 招聘中
- Kobe Minimally Invasive Cancer Center /ID# 277469
-
-
Kanagawa
-
Sagamihara-shi、Kanagawa、日本、252-0375
- 招聘中
- Kitasato University Hospital /ID# 277012
-
-
Miyagi
-
Sendai、Miyagi、日本、981-0914
- 招聘中
- Sendai Kousei Hospital /ID# 277023
-
-
Miyazaki
-
Miyazaki、Miyazaki、日本、889-1692
- 招聘中
- University of Miyazaki Hospital /ID# 277020
-
-
Okayama-ken
-
Kurashiki-shi、Okayama-ken、日本、710-8602
- 招聘中
- Kurashiki Central Hospital /ID# 276995
-
-
Shizuoka
-
Fujieda、Shizuoka、日本、426-0077
- 招聘中
- Fujieda Municipal General Hospital /ID# 277025
-
-
Wakayama
-
Wakayama、Wakayama、日本、641-8510
- 招聘中
- Wakayama Medical University Hospital /ID# 276997
-
-
-
-
Arizona
-
Chandler、Arizona、美国、85224
- 招聘中
- Ironwood Cancer and Research Center /ID# 276370
-
-
Arkansas
-
Little Rock、Arkansas、美国、72205
- 招聘中
- University of Arkansas for Medical Sciences /ID# 272923
-
-
California
-
Los Angeles、California、美国、90067
- 招聘中
- Valkyrie Clinical Trials /ID# 271322
-
Los Angeles、California、美国、90025
- 招聘中
- Start Los Angeles /ID# 284999
-
Oxnard、California、美国、93030
- 招聘中
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- 完全的
- Yale New Haven Hospital /ID# 271584
-
-
Florida
-
Jacksonville、Florida、美国、32256
- 招聘中
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
-
Ocala、Florida、美国、34474
- 招聘中
- Ocala Oncology Center /ID# 273697
-
Pembroke Pines、Florida、美国、33028
- 招聘中
- Memorial Hospital West /ID# 270313
-
St. Petersburg、Florida、美国、33701-4732
- 招聘中
- Comprehensive Hematology Oncology /ID# 270422
-
St. Petersburg、Florida、美国、33705
- 招聘中
- Florida Cancer Specialists - North /ID# 271995
-
West Palm Beach、Florida、美国、33401
- 招聘中
- Florida Cancer Specialists - East /ID# 271993
-
-
Georgia
-
Athens、Georgia、美国、30607
- 招聘中
- University Cancer and Blood Center /ID# 270969
-
Marietta、Georgia、美国、30060
- 招聘中
- Northwest Georgia Oncology Centers /ID# 275374
-
Savannah、Georgia、美国、31404
- 完全的
- Memorial University Medical Center /ID# 272467
-
-
Hawaii
-
Honolulu、Hawaii、美国、96819
- 招聘中
- Kaiser Permanente Moanalua Medical Center /ID# 272916
-
-
Illinois
-
Chicago、Illinois、美国、60607
- 招聘中
- University of Illinois Hospital and Health Sciences System /ID# 275345
-
Niles、Illinois、美国、60714
- 招聘中
- Illinois Cancer Specialists /ID# 274678
-
Peoria、Illinois、美国、61637-0001
- 招聘中
- OSF St. Francis Medical Center /ID# 281591
-
Springfield、Illinois、美国、62702
- 招聘中
- Springfield Clinic - First /ID# 272576
-
-
Nebraska
-
Lincoln、Nebraska、美国、68506
- 招聘中
- Nebraska Hematology-Oncology /ID# 272970
-
Omaha、Nebraska、美国、68130
- 招聘中
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
-
-
Nevada
-
Reno、Nevada、美国、89502
- 招聘中
- Renown Regional Medical Center /ID# 273535
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816-4096
- 招聘中
- Astera Cancer Care /ID# 272359
-
Teaneck、New Jersey、美国、07666
- 招聘中
- Regional Cancer Care Associates /ID# 270783
-
-
New York
-
The Bronx、New York、美国、10461
- 招聘中
- Montefiore Medical Center - Einstein Campus /ID# 277169
-
Westbury、New York、美国、11590
- 招聘中
- Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
-
-
North Carolina
-
Pinehurst、North Carolina、美国、28374
- 招聘中
- FirstHealth of the Carolinas- Speciality Center /ID# 272924
-
-
Ohio
-
Perrysburg、Ohio、美国、43551
- 招聘中
- Mercy Health - Perrysburg Cancer Center /ID# 270536
-
Zanesville、Ohio、美国、43701
- 招聘中
- Genesis Healthcare System /ID# 273361
-
-
Pennsylvania
-
Sayre、Pennsylvania、美国、18840
- 招聘中
- Guthrie Robert Packer Hospital /ID# 270316
-
York、Pennsylvania、美国、17403
- 招聘中
- Cancer Care Associates Of York /ID# 270971
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- 招聘中
- Medical University of South Carolina /ID# 273272
-
Greenville、South Carolina、美国、29607
- 招聘中
- Saint Francis Cancer Center - Greenville /ID# 276368
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- SCRI Oncology Partners /ID# 270162
-
-
Texas
-
Dallas、Texas、美国、75246
- 招聘中
- Texas Oncology - Dallas - Worth Street /ID# 278947
-
Tyler、Texas、美国、75702
- 招聘中
- Texas Oncology - Northeast Texas /ID# 272000
-
-
Utah
-
Ogden、Utah、美国、84405
- 招聘中
- Community Cancer Trials Of Utah /ID# 276598
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- Virginia Cancer Specialists - Fairfax /ID# 272004
-
-
Washington
-
Spokane、Washington、美国、99208
- 招聘中
- Medical Oncology Associates - Spokane /ID# 277172
-
Tacoma、Washington、美国、98405
- 招聘中
- Northwest Medical Specialties Tacoma /ID# 270534
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Projected life expectancy of at least 12 weeks.
- Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
- Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
- Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
- Actionable alterations in genes other than EGFR are permitted.
- Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
- Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.
Exclusion Criteria:
- Adenosquamous or neuroendocrine histology, or sarcomatoid features.
- EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
- Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
- Received prior docetaxel therapy.
- Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
- History of other malignancies except those stated in the protocol.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
- Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
- Major surgery within 21 days prior to randomization.
- Clinically significant condition(s) including but not limited to those listed in the protocol.
- Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
- Grade >= 2 edema or lymphedema.
- Grade >= 2 ascites or pleural effusion.
- Grade >= 2 neuropathy.
- Active uncontrolled bacterial or viral infection.
- Active corneal disorder.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Telisotuzumab Vedotin Dose A
Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration. |
Intravenous (IV) Infusion
其他名称:
|
|
实验性的:Telisotuzumab Vedotin Dose B
Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration. |
Intravenous (IV) Infusion
其他名称:
|
|
实验性的:Telisotuzumab Vedotin Dose C
Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration. |
Intravenous (IV) Infusion
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
大体时间:Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
大体时间:Up to Approximately 3 Years
|
ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
大体时间:Up to Approximately 3 Years
|
Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2) |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
大体时间:Up to Approximately 3 Years
|
Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
大体时间:Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Grade 5 Treatment-Emergent AEs
大体时间:Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Objective Response (OR) by Blinded Independent Central Review (BICR)
大体时间:Up to Approximately 3 Years
|
OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1. |
Up to Approximately 3 Years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
大体时间:Up to 26 Weeks
|
Concentrations of telisotuzumab vedotin conjugate in serum. |
Up to 26 Weeks
|
|
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
大体时间:Up to 26 Weeks
|
Concentrations of MMAE payload in plasma. |
Up to 26 Weeks
|
|
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
大体时间:Up to 26 Weeks
|
Percentage of participants with ADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
大体时间:Up to 26 Weeks
|
Percentage of participants with nADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
大体时间:Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present). |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
大体时间:Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants. |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Duration of Response (DoR) by BICR
大体时间:Up to Approximately 3 Years
|
DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Progression-Free Survival (PFS) by BICR
大体时间:Up to Approximately 3 Years
|
PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
大体时间:Up to Approximately 3 Years
|
OS will be defined as the time from randomization to death from any cause. |
Up to Approximately 3 Years
|
合作者和调查者
赞助
调查人员
- 研究主任:ABBVIE INC.、AbbVie
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- M25-274
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 共享时间框架
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 共享访问标准
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.